Iovance Biotherapeutics Inc. (NASDAQ:IOVA) and Intec Pharma Ltd. (NASDAQ:NTEC), both competing one another are Biotechnology companies. We will compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Iovance Biotherapeutics Inc.||N/A||0.00||123.58M||-1.37||0.00|
|Intec Pharma Ltd.||N/A||0.00||43.54M||-1.40||0.00|
Table 1 highlights Iovance Biotherapeutics Inc. and Intec Pharma Ltd.â€™s gross revenue, earnings per share (EPS) and valuation.
Table 2 shows the return on assets, return on equity and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Iovance Biotherapeutics Inc.||0.00%||-43.7%||-41.3%|
|Intec Pharma Ltd.||0.00%||0%||0%|
Insider & Institutional Ownership
The shares of both Iovance Biotherapeutics Inc. and Intec Pharma Ltd. are owned by institutional investors at 0% and 39.64% respectively. Iovance Biotherapeutics Inc.â€™s share held by insiders are 0.4%. Comparatively, insiders own roughly 11.81% of Intec Pharma Ltd.â€™s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Iovance Biotherapeutics Inc.||7.34%||23.06%||21.6%||-31.55%||-37.96%||27.23%|
|Intec Pharma Ltd.||-5.95%||4.85%||37.69%||116.32%||34.75%||9.02%|
For the past year Iovance Biotherapeutics Inc. has stronger performance than Intec Pharma Ltd.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The companyÃ‚â€™s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patientsÃ‚â€™ tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patientÃ‚â€™s TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas MD Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÃ‚â€™s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÃ‚â€™s disease symptoms in advanced ParkinsonÃ‚â€™s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.